Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, ...
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the promising potential of Mind Medicine’s MM120 treatment. The company is advancing MM120, a ...
Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT), for the ...
MM120 ODT uses Catalent’s Zydis ODT technology. Credit: MindMed Inc./Business Wire. Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of ...